NCT04789096 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04789096
Title	Tucatinib Together with Pembrolizumab and Trastuzumab (TUGETHER)
Acronym	TUGETHER
Recruitment	Terminated
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Breast Cancer Trials, Australia and New Zealand
Indications	Her2-receptor positive breast cancer
Therapies	Pembrolizumab + Trastuzumab + Tucatinib Capecitabine + Pembrolizumab + Trastuzumab + Tucatinib
Age Groups:	adult \| senior
Covered Countries	AUS

Filter rows:

Showing 1 to 15 of 15 entries

Facility	City	State	Zip	Country	Details
Austin Hospital	Heidelberg	Victoria	3084	Australia	Details
Calvary Mater Newcastle	Waratah	New South Wales	2310	Australia	Details
Coffs Harbour Health Campus	Coffs Harbour	New South Wales	2450	Australia	Details
Epworth Richmond Hospital	Richmond	Victoria	3121	Australia	Details
Gosford Hospital	Gosford	New South Wales	2250	Australia	Details
Icon Cancer Centre Hobart	Hobart	Tasmania	7000	Australia	Details
Macquarie University	Macquarie Park	New South Wales	2109	Australia	Details
Nepean Cancer Care Centre	Kingswood	New South Wales	2747	Australia	Details
Peter MacCallum Cancer Centre	Parkville	Victoria	3002	Australia	Details
Prince of Wales Hospital	Randwick	New South Wales	2031	Australia	Details
Royal Adelaide Hospital	Adelaide	South Australia	5000	Australia	Details
Sunshine Coast University Hospital	Birtinya	Queensland	4575	Australia	Details
Sunshine Hospital	St Albans	Victoria	3021	Australia	Details
Westmead Hospital	Westmead	New South Wales	2145	Australia	Details
Wollongong Hospital	Wollongong	New South Wales	2500	Australia	Details

Showing 1 to 15 of 15 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT04789096Clinical Trial Detail